Kamada and Chiesi Farmaceutici S.p.A. Mutually Agree to Terminate European Distribution Agreement for Inhaled Alpha-1 Antitrypsin Therapy for Treatment of Alpha-1 Antitrypsin Deficiency

Press Release / Nov. 22, 2017

Kamada announced that the Company and Chiesi Farmaceutici S.p.A., a fully integrated European Pharmaceutical company focused on respiratory disease and special care products, have mutually agreed to terminate the parties’ European distribution agreement related to Kamada’s inhaled Alpha-1 Antitrypsin (AAT) therapy for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).

Kamada Announces New Supply Agreement with International Organization for KamRAB for Post-Exposure Prophylaxis Against Rabies Infection

Press Release / Nov. 21, 2017

Kamada announced today that it has signed a supply agreement with an undisclosed international organization for KamRAB [rabies immune globulin (Human)].  

Kamada Reports Financial Results for Third Quarter and First Nine Months of 2017

Press Release / Nov. 14, 2017

Kamada announced financial results for the three and nine months ended September 30, 2017.

Amended Notice of 2017 Annual General Meeting of Shareholders

Press Release / Nov. 10, 2017

On October 26, 2017, Kamada Ltd. announced the 2017 Annual General Meeting of shareholders of the Company to be held on November 30, 2017.


Kamada to Announce Third Quarter 2017 Financial Results and Host Conference Call on November 13

Press Release / Nov. 8, 2017

Kamada announced today that it will release financial results for the third quarter ended September 30, 2017, prior to the open of the U.S. financial markets on Monday, November 13.

Kamada Announces Top-line Results of Phase 2 Trial of Alpha-1 Antitrypsin in Newly Diagnosed Type-1 Diabetes Patients

Press Release / Nov. 1, 2017

Efficacy trend was demonstrated in the pre-determined subgroup of patients between the ages of 12 to 18, treated with the higher dose of 120mg/kg. The positive trend was observed in this age group for all three key efficacy measures of Type-1 Diabetes.

Kamada Announces CFO Transition Gil Efron, Deputy CEO and CFO, to Depart Kamada at End of Year; Chaime Orlev to Assume CFO Duties

Press Release / Sep. 18, 2017

Kamada announced that Gil Efron, Deputy Chief Executive Officer (Deputy CEO) & Chief Financial Officer (CFO) recently informed the Company of his plan to leave at the end of the year.

Kamada to Present Corporate Overview at Two Investor Conferences in September

Press Release / Sep. 6, 2017

Kamada announced today that Amir London, Chief Executive Officer, will provide a corporate overview at the Cantor Fitzgerald Global Healthcare Conference and the Ladenburg Thalmann 3rd Annual Healthcare Conference.

Kamada Announces Collaboration with BGN Technologies for Advanced Alpha-1 Antitrypsin Research with a Focus on Mechanism of Action

Press Release / Sep. 6, 2017

Kamada announced today a collaboration for advanced research on Alpha-1 Antitrypsin (AAT) with a focus on mechanism of action with BGN Technologies (BGN), the business arm of Ben Gurion University (BGU).  Professor Eli Lewis, Department of Clinical Biochemistry and Pharmacology at BGU, and one of the world’s foremost AAT investigators, will lead the collaboration.

out of 145 items.